A preliminary immunohistochemical study of signal transducer and activator of transcription (STAT) proteins in primary oral malignant melanoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: United States NLM ID: 101576782 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-4411 (Electronic) NLM ISO Abbreviation: Oral Surg Oral Med Oral Pathol Oral Radiol Subsets: MEDLINE
    • Publication Information:
      Original Publication: New York, NY : Elsevier
    • Subject Terms:
      Melanoma/*metabolism ; Melanoma/*pathology ; Mouth Neoplasms/*metabolism ; Mouth Neoplasms/*pathology ; STAT1 Transcription Factor/*metabolism ; STAT3 Transcription Factor/*metabolism ; STAT5 Transcription Factor/*metabolism ; Tumor Suppressor Proteins/*metabolism; Aged ; Aged, 80 and over ; Biomarkers, Tumor/metabolism ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Prognosis ; Signal Transduction
    • Abstract:
      Objective: Primary oral malignant melanoma (POMM) is a rare type of malignancy with a very poor prognosis, the molecular pathogenesis of which remains elusive. The aim of this study was to assess the expression status of signal transducer and activator of transcription (STAT) proteins in POMM.
      Study Design: Six POMMs were included in the study. Total protein levels of STAT1, STAT3, and STAT5a, as well as the tyrosine phosphorylated (activated) form of STAT3 (pSTAT3), were assessed immunohistochemically.
      Results: Immunohistochemical evaluation of total STAT3 revealed diffuse and strong cytoplasmic and nuclear expression in the majority of tumor cells of all cases, whereas activated pSTAT3 had mostly mild nuclear expression in 5%-40% of malignant melanocytes in all cases. Evaluation of STAT1 and STAT5a identified mainly mild cytoplasmic expression in the absence of nuclear localization.
      Conclusion: The identification of aberrant STAT3 expression and activation in oral malignant melanocytes supports a possible role of this molecule in POMM. In contrast, STAT5a has only limited cytoplasmic expression, mitigating against its involvement in POMM. Also, STAT1's low levels may have implications for POMM sensitivity to interferon-based therapeutic strategies, considering the role of this molecule in cutaneous melanoma immunotherapy.
      (Copyright © 2018. Published by Elsevier Inc.)
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (STAT1 Transcription Factor)
      0 (STAT1 protein, human)
      0 (STAT3 Transcription Factor)
      0 (STAT5 Transcription Factor)
      0 (STAT5A protein, human)
      0 (Tumor Suppressor Proteins)
    • Publication Date:
      Date Created: 20171219 Date Completed: 20180725 Latest Revision: 20180725
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.oooo.2017.10.007
    • Accession Number:
      29249519